US paves way for vaccine patent waiver but drugmakers will want compensation
To boost Covid-19 vaccine production capacity, the Biden administration will also need to provide funding to build new manufacturing sites
07 May 2021 - 09:36
Maplewood/Washington — US support for waiving intellectual property (IP) rights on Covid-19 vaccines could be a tactic to convince drugmakers to back less drastic steps such as sharing technology and expanding joint ventures to quickly boost global production, lawyers said on Thursday.
“I think the end result that most players are looking for here is not IP waiver in particular, it’s expanded global access to the vaccines,” said professor Lisa Ouellette of Stanford Law School...
Would you like to comment on this article?
Sign up (it's quick and free) or sign in now.
Please read our Comment Policy before commenting.
Subscribe now to unlock this article.
Support BusinessLIVE’s award-winning journalism for R129 per month (digital access only).
There’s never been a more important time to support independent journalism in SA. Our subscription packages now offer an ad-free experience for readers.
Cancel anytime.
Questions? Email helpdesk@businesslive.co.za or call 0860 52 52 00. Got a subscription voucher? Redeem it now.